mortality/aging
|
• mice do not survive beyond 12 months of age
|
|
• 80% of rate die by 4 weeks
|
nervous system
astrocytosis
(
J:170480
)
|
• starting in early postnatal stages
• astrocyte proliferation is increased compared to in control cells
• astrocytes exhibit resistance to cycloheximide-induced apoptosis compared with control cells
• retinal astrocyte spreading is decreased compared to in control mice
|
|
• abnormal cytoarchitecture
|
|
• brain capillaries are dilated and less organized and dense than in control mice
• between 3 weeks and 12 months, two-thirds of mice develop cerebrovascular lesions resembling cavernomas unlike in control mice
|
hydrocephaly
(
J:170480
)
|
• at 2 months
|
cardiovascular system
|
• brain capillaries are dilated and less organized and dense than in control mice
• between 3 weeks and 12 months, two-thirds of mice develop cerebrovascular lesions resembling cavernomas unlike in control mice
|
|
• endothelial cell migration is delayed compared to in control mice
|
|
• brain capillaries
|
neoplasm
|
• between 3 weeks and 12 months, two-thirds of mice develop cerebrovascular lesions resembling cavernomas unlike in control mice
• mice develop cavernomas in the spinal cord unlike wild-type mice
|
behavior/neurological
|
• unsteady
|
growth/size/body
cellular
|
• endothelial cell migration is delayed compared to in control mice
|
astrocytosis
(
J:170480
)
|
• starting in early postnatal stages
• astrocyte proliferation is increased compared to in control cells
• astrocytes exhibit resistance to cycloheximide-induced apoptosis compared with control cells
• retinal astrocyte spreading is decreased compared to in control mice
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| cerebral cavernous malformation 3 | DOID:0060671 |
OMIM:603285 |
J:170480 | |


Analysis Tools